3 October 2024 F2G’s September $100m funding round provides the company with crucial funds to
renavigate approval of its lead drug, olorofim. The substantial financing also
highlights the paucity of novel antifungal products in the clinic.
Italian pharma major Recordati saw its shares rise more than 5% to 52.00 euros in early trading, as it announced a deal to expand its portfolio of marketed rare disease medicines. 4 October 2024
Paris-based asset manager Kurma Partners has raised 140 million euros ($154 million), successfully completing the first closing of Biofund IV 4 October 2024
Bristol Myers Squibb has received a new approval from the US Food and Drug Administration for its blockbuster checkpoint blocker, Opdivo (nivolumab). 4 October 2024
Singapore’s Agency for Science, Technology and Research (A*STAR) and US biotech incubator Flagship Pioneering have agree to collaborate on advancing health and sustainability outcomes in Singapore and the broader Asia Pacific region. 4 October 2024
The US Food and Drug Administration (FDA) has removed the partial clinical hold on delpacibart etedesiran (del-desiran/AOC 1001), an investigational treatment designed to address the root cause of myotonic dystrophy type 1 (DM1), under development by US biotech Avidity Biosciences . 4 October 2024
The US Food and Drug Administration (FDA) has granted the Gilead Sciences subsidiary Kite a Regenerative Medicine Advanced Therapy Designation (RMAT) for Yescarta (axicabtagene ciloleucel) for adults with newly-diagnosed, high-risk large B-cell lymphoma (LBCL). 3 October 2024
Kedrion Biopharma has finalized an agreement with Germany-based Biotest for the long-term commercialization and distribution of Yimmugo (immune globulin) in the USA. 3 October 2024
US clinical-stage biotech Arcus Biosciences has entered into a clinical trial collaboration with AstraZeneca on renal cancer treatments. 3 October 2024
PeptiDream says that its wholly-owned PDRadiopharma subsidiary has entered into a strategic partnership with French nuclear medicines firm Curium. 3 October 2024
Privately-held Ferring Pharmaceuticals has announced the opening of a global manufacturing hub in Finland for the drug substance of its intravesical non-replicating gene therapy Adstiladrin (nadofaragene firadenovec-vncg). 3 October 2024
Shares of UK drug developer Hemogenyx Pharmaceuticals rose as much as 9% and closed up 5.9% at 1.70 pence yesterday on the news of a further investment from Prevail Partners. 3 October 2024
UK-based biotech Resolution Therapeutics has announced the completion of a £63.5 million ($76.8 million) series B financing round led by Syncona. 3 October 2024
The BioIndustry Association (BIA), in collaboration with the Centre for Process Innovation (CPI), has published a new report on the UK’s mRNA sector. 2 October 2024
Aspen Neuroscience, a private biotechnology company specializing in autologous cell therapies, has announced the opening of a major new facility near its headquarters in San Diego. 2 October 2024
Privately-held UK biotech Curve Therapeutics today announced the further strengthening of its leadership team with the appointments of Andre Hoekema as chairman of the board and Cora Griffin as head of business development. 2 October 2024
The US Food and Drug Administration (FDA) has posted a safety communication to inform the public and healthcare providers that the agency has required and approved labeling changes to the US Prescribing Information (USPI) for all licensed BCMA-directed and CD19-directed genetically modified autologous CAR-T cell immunotherapies. 20 April 2024
Swiss drugmaker Ferring Pharmaceuticals has inked a deal with South Korean contract manufacturing and development organization (CDMO) SK pharmteco. 19 April 2024
Connecticut, USA-based biotech company Biohaven has priced an underwritten public offering with the goal of raising approximately $230 million. 19 April 2024
Dutch rare diseases biotech firm ProQR Therapeutics saw its shares leap more than 11% to $2.07 today, after it announced its successful defense against opposition filed against a key patent for its ADAR-mediated RNA editing platform Axiomer. 19 April 2024
Japanese drugmaker Chugai today announced that it concluded a license agreement with its majority owner, Swiss pharma giant Roche, for zilebesiran, 19 April 2024
Former Novartis executive Aurelia Caparrós has joined Amarna Therapeutics, a privately-held Dutch biotech developing gene therapies in a range of rare and prevalent diseases, including type 1 diabetes. 19 April 2024
A rare success in Parkinson’s disease is good news not just for the company behind the research - Cerevel Therapeutics - but also for AbbVie. 19 April 2024
Japanese pharma giant Takeda has picked up a new approval for subcutaneous Entyvio (vedolizumab), for maintenance therapy of severely active Crohn’s disease. 19 April 2024
US immune therapies and vaccines developer Corner Therapeutics has raised $54 million to create vaccines that confer lifelong protection from cancer and infectious diseases. 19 April 2024
American biopharma companies have criticised new European pharmaceutical legislation designed to make medicines more available, accessible and affordable. 18 April 2024
US pharma major Eli Lilly is on the brink of reshaping the pharmaceutical landscape with its ground-breaking treatments, Mounjaro (tirzepatide) for diabetes and marketed as Zepbound for obesity and the highly anticipated donanemab for early symptomatic Alzheimer’s disease. 17 April 2024
Swiss pharma giant Roche today released new data from the Phase III OCARINA II study (S31.006) of Ocrevus (ocrelizumab), an investigational twice-yearly, 10-minute subcutaneous (SC) injection. 17 April 2024
Ahead of a planned presentation at the American Thoracic Society meeting next month, US biotech major Amgen has released an update regarding the results of the Phase IIa COURSE trial for Tezspire (tezepelumab-ekko) in chronic obstructive pulmonary disease (COPD), 17 April 2024
US privately-held Kumquat Biosciences today announced a strategic and exclusive collaboration with Japan’s Takeda to develop and commercialize a novel immuno-oncology (I-O) small molecule inhibitor as a mono- and/or combination-therapy. 17 April 2024
Novartis has announced data from the ALITHIOS open-label extension study showing sustained efficacy of first-line, continuous Kesimpta (ofatumumab) treatment for up to six years in recently diagnosed treatment-naïve people living with relapsing multiple sclerosis (RMS). 17 April 2024
A change of therapeutic focus, a full rebrand and a major cash injection will shake things up considerably at Massachusetts, USA-based Cullinan Therapeutics. 17 April 2024
North Carolina, USA-based KBI Biopharma has appointed Jean-Baptiste Agnus as chief business officer, joining the company’s executive team. 17 April 2024
US clinical-stage cell therapy developer Vittoria Biotherapeutics has announced that Keith Westby has joined the company as its inaugural chief operating officer (COO). 16 April 2024
Sign up to receive email updates Join industry leaders for a daily roundup of biotech & pharma news
Company Spotlight
A pre-clinical stage biopharmaceutical group developing new medicines and treatments to treat blood and autoimmune disease and to bring the curative power of bone marrow transplantation to a greater number of patients suffering from otherwise incurable life-threatening diseases.